Related Experiment Videos
Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation
Troy J Kemp1, Jill M Moore, Thomas S Griffith
1Department of Urology, Interdisciplinary Graduate Program in Immunology, and Prostate Cancer Research Program of the Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.
Journal of Immunology (Baltimore, Md. : 1950)
|July 9, 2004
Summary
CpG-A oligodeoxynucleotides (ODN) enhance antitumor immunity by inducing TRAIL/Apo-2L expression in B cells, enabling them to kill tumor cells. This pathway is further boosted by IFN-alpha and anti-CD40 mAb, highlighting B cells as key players in anti-tumor responses.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- CpG oligodeoxynucleotides (ODN) are known for their immunostimulatory effects, including antitumor responses.
- CpG ODN are classified into CpG-A and CpG-B types, differing in their immune cell activation profiles and cytokine production.
- Previous studies showed CpG-B ODN induces TRAIL/Apo-2L-mediated tumor cell killing by CD14+ peripheral blood mononuclear cells (PBMC).
Purpose of the Study:
- To investigate the expression and activity of TRAIL/Apo-2L induced by CpG-A ODN in PBMC.
- To compare the efficacy of CpG-A and CpG-B ODN in inducing IFN-alpha production and TRAIL/Apo-2L-mediated tumor cell killing.
- To explore the role of different immune cell subsets, particularly B cells, in CpG ODN-induced antitumor activity.
Main Methods:
- Stimulation of PBMC with CpG-A and CpG-B ODN.
- Analysis of IFN-alpha production and TRAIL/Apo-2L expression in various PBMC subsets (CD3+, CD14+, CD19+, CD56+).
- Assessment of tumor cell killing by isolated PBMC subsets and the effect of IFN-alpha and anti-CD40 mAb on TRAIL/Apo-2L expression in B cells.
Main Results:
- CpG-A ODN induced higher IFN-alpha production and TRAIL/Apo-2L-mediated tumor cell killing compared to CpG-B ODN.
- CpG-A ODN stimulation led to high TRAIL/Apo-2L expression across multiple PBMC subsets, including CD19+ B cells.
- Isolated CD19+ B cells demonstrated TRAIL/Apo-2L-dependent tumor cell killing, which was enhanced by IFN-alpha and further augmented by anti-CD40 mAb.
Conclusions:
- CpG-A ODN effectively induce TRAIL/Apo-2L expression and antitumor activity in human PBMC, with B cells playing a significant role.
- This study provides the first evidence of human B cell-mediated tumor cell killing via TRAIL/Apo-2L.
- The findings suggest that CpG-A ODN, potentially in combination with IFN-alpha and anti-CD40, could be a promising strategy for cancer immunotherapy.